Single User License
INR 101235
Site License
INR 202470
Corporate User License
INR 303705

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


NicOx S.A.-Product Pipeline Review-2015

NicOx S.A.-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

NicOx S.A.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'NicOx S.A.-Product Pipeline Review-2015', provides an overview of the NicOx S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of NicOx S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of NicOx S.A. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of NicOx S.A.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the NicOx S.A.'s pipeline products

Reasons To Buy

Evaluate NicOx S.A.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of NicOx S.A. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the NicOx S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of NicOx S.A. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of NicOx S.A.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of NicOx S.A. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

NicOx S.A. Snapshot 6

NicOx S.A. Overview 6

Key Information 6

Key Facts 6

NicOx S.A.-Research and Development Overview 7

Key Therapeutic Areas 7

NicOx S.A.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

NicOx S.A.-Pipeline Products Glance 14

NicOx S.A.-Late Stage Pipeline Products 14

Filing rejected/Withdrawn Products/Combination Treatment Modalities 14

Phase III Products/Combination Treatment Modalities 15

NicOx S.A.-Clinical Stage Pipeline Products 16

Phase I Products/Combination Treatment Modalities 16

NicOx S.A.-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

NicOx S.A.-Unknown Stage Pipeline Products 19

Unknown Products/Combination Treatment Modalities 19

NicOx S.A.-Drug Profiles 20

naproxcinod 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

cetirizine hydrochloride 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

fluticasone propionate 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

cerdulatinib 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

NCX-1021 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

NCX-250 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

NCX-422 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

NCX-429 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

NCX-434 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

NCX-466 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NCX-470 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

NCX-667 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Activate sGC for Ophthalmology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules for Cardiovascular Disease 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

NicOx S.A.-Pipeline Analysis 35

NicOx S.A.-Pipeline Products by Target 35

NicOx S.A.-Pipeline Products by Route of Administration 37

NicOx S.A.-Pipeline Products by Molecule Type 38

NicOx S.A.-Pipeline Products by Mechanism of Action 39

NicOx S.A.-Recent Pipeline Updates 40

NicOx S.A.-Dormant Projects 44

NicOx S.A.-Discontinued Pipeline Products 45

Discontinued Pipeline Product Profiles 45

NCX-1000 45

naproxcinod 45

NCX-1236 45

NCX-226 45

NCX-285 45

NCX-6560 46

NicOx S.A.-Locations And Subsidiaries 47

Head Office 47

Other Locations & Subsidiaries 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

NicOx S.A., Key Information 6

NicOx S.A., Key Facts 6

NicOx S.A.-Pipeline by Indication, 2015 8

NicOx S.A.-Pipeline by Stage of Development, 2015 10

NicOx S.A.-Monotherapy Products in Pipeline, 2015 11

NicOx S.A.-Partnered Products in Pipeline, 2015 12

NicOx S.A.-Partnered Products/ Combination Treatment Modalities, 2015 13

NicOx S.A.-Filing rejected/Withdrawn, 2015 14

NicOx S.A.-Phase III, 2015 15

NicOx S.A.-Phase I, 2015 16

NicOx S.A.-Preclinical, 2015 17

NicOx S.A.-Discovery, 2015 18

NicOx S.A.-Unknown, 2015 19

NicOx S.A.-Pipeline by Target, 2015 36

NicOx S.A.-Pipeline by Route of Administration, 2015 37

NicOx S.A.-Pipeline by Molecule Type, 2015 38

NicOx S.A.-Pipeline Products by Mechanism of Action, 2015 39

NicOx S.A.-Recent Pipeline Updates, 2015 40

NicOx S.A.-Dormant Developmental Projects,2015 44

NicOx S.A.-Discontinued Pipeline Products, 2015 45

NicOx S.A., Subsidiaries 47

List of Figures

NicOx S.A.-Pipeline by Top 10 Indication, 2015 8

NicOx S.A.-Pipeline by Stage of Development, 2015 10

NicOx S.A.-Monotherapy Products in Pipeline, 2015 11

NicOx S.A.-Partnered Products in Pipeline, 2015 12

NicOx S.A.-Pipeline by Top 10 Target, 2015 35

NicOx S.A.-Pipeline by Top 10 Route of Administration, 2015 37

NicOx S.A.-Pipeline by Top 10 Molecule Type, 2015 38

NicOx S.A.-Pipeline Products by Top 10 Mechanism of Action, 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of NicOx S.A.; NicOx S.A. - Key Therapeutics; NicOx S.A. - Pipeline Overview and Promising Molecules; NicOx S.A. - News; NicOx S.A. - Latest Updates; NicOx S.A. - Pipeline; NicOx S.A. - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com